Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a...

|By:, SA News Editor

Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%.